Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study

@article{Schweighofer2012ClinicalSA,
  title={Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study},
  author={C. Schweighofer and A. Tuchscherer and S. Sperka and T. Meyer and B. Rattel and S. Stein and S. Ismail and T. Elter and P. Staib and M. Reiser and M. Hallek},
  journal={Cancer Immunology, Immunotherapy},
  year={2012},
  volume={61},
  pages={2367-2373}
}
Abstract1D09C3 is a human monoclonal IgG4-type antibody against human leukocyte antigen-DR (HLA-DR) which has demonstrated pro-apoptotic activity against lymphoid tumors in vitro and in vivo. [...] Key Method Fourteen patients with relapsed/refractory B cell type leukemia/lymphoma were treated and followed after up to 4 weekly infusions of 1D09C3, administered in 6 dose levels at 0.25–8 mg/kg/day. Treatment was tolerated well with mostly mild side effects. The most common grade III–IV toxicities were…Expand
Trial Watch
Polymorphic Region-Specific Antibody for Evaluation of Affinity-Associated Profile of Chimeric Antigen Receptor
B cell MHC class II signaling: A story of life and death.
Tumor-targeting monoclonal antibodies in cancer therapy
  • 2014

References

SHOWING 1-10 OF 24 REFERENCES
A phase 1a clinical trial of LYM‐1 monoclonal antibody serotherapy in patients with refractory b cell malignancies
Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells
Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
...
1
2
3
...